Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

NCT07468071 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer
Advanced Solid Tumors Harboring the KRAS G12C Mutation

Interventions

DRUG: Opnurasib
DRUG: TNO155
DRUG: trametinib
BIOLOGICAL: cetuximab
BIOLOGICAL: tislelizumab

Sponsor

Novartis Pharmaceuticals